Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Broad Institute · Dana-Farber Cancer Institute · +14 more institutions
Abstract
Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic melanoma by inhibiting immune checkpoint activity, but clinical predictors of response to these therapies remain incompletely characterized. To investigate the roles of tumor-specific neoantigens and alterations in the tumor microenvironment in the response to ipilimumab, we analyzed whole exomes from pretreatment melanoma tumor biopsies and matching germline tissue samples from 110 patients. For 40 of these patients, we also obtained and analyzed transcriptome data from the pretreatment tumor samples. Overall mutational load,…
Citation impact
- FWCI
- 108.51
- Percentile
- 100%
- References
- 42
Authors
22- EMEliezer M. Van AllenCorresponding
Broad Institute, Dana-Farber Cancer Institute
- DMDiana MiaoCorresponding
Broad Institute, Dana-Farber Cancer Institute
- BSBastian SchillingCorresponding
German Cancer Research Center, University of Duisburg-Essen
- SASachet A. Shukla
Broad Institute, Dana-Farber Cancer Institute
- CUChristian U. Blank
The Netherlands Cancer Institute
Topics & keywords
- Ipilimumab
- CTLA-4
- Immune checkpoint
- Tumor microenvironment
- Melanoma
- Immunotherapy
- Immune system
- Cancer research
- Good health and well-being